Sarah Smith

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 283 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Response of recurrent medulloblastoma to low-dose oral etoposide.

David M. Ashley, L Meier, Tracy Kerby et al. · Journal of Clinical Oncology · 1996 · 137 citations · Full text

Medicine, Oncology, Pharmacology +17

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

Nicole Mayer-Hamblett, Félix Ratjen, Renee Russell et al. · The Lancet Respiratory Medicine · 2022 · 126 citations · Full text

Pharmacy, Pharmacotherapy, Good Clinical Practice +8

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Joseph Gligorov, Beyhan Ataseven, Mark Verrill et al. · European Journal of Cancer · 2017 · 46 citations · Full text

Medicine, Oncology, Pharmacology +17

A taxonomic monograph of Nearctic Scolytus Geoffroy (Coleoptera, Curculionidae, Scolytinae)

Sarah Smith, Anthony I. Cognato · ZooKeys · 2014 · 38 citations · Full text

Life Sciences, Entomology, Zoology +17